Aspen Aerogels (ASPN)
Makes aerogel materials for EV battery barriers and energy-industrial insulation.
BlackRock Inc. Buys Shares of 5,277,148 Aspen Aerogels, Inc. $ASPN
BlackRock Inc. bought a new position in Aspen Aerogels, Inc. (NYSE: ASPN) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 5,277,148 shares of the construction company's stock, valued at approximately $33,457,000. BlackRock Inc. owned 6.37% of Aspen Aerogels as of its most
Aspen Aerogels, Inc. $ASPN Shares Sold by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP lessened its position in shares of Aspen Aerogels, Inc. (NYSE: ASPN) by 37.3% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,256,480 shares of the construction company's stock after selling 747,483 shares during the quarter. Dimensional Fund
Aspen Aerogels, Inc. (ASPN) Q2 2026 Earnings Call Transcript
Aspen Aerogels, Inc. (ASPN) Q2 2026 Earnings Call Transcript
Aspen Aerogels (ASPN) Reports Q2 Loss, Beats Revenue Estimates
Aspen Aerogels (ASPN) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
AI-powered Initiative Aims to Enhance Customer Engagement, Accelerate Commercial Execution and Support Long-Term Growth
Aspen Aerogels, Inc. (ASPN) Q1 2026 Earnings Call Transcript
Aspen Aerogels, Inc. (ASPN) Q1 2026 Earnings Call Transcript
Aspen Aerogels (ASPN) Reports Q1 Loss, Tops Revenue Estimates
Aspen Aerogels (ASPN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.06 per share a year ago.
Aspen Aerogels, Inc. (ASPN) Q4 2025 Earnings Call Transcript
Aspen Aerogels, Inc. (ASPN) Q4 2025 Earnings Call Transcript
AWM Investment Company Inc. Cuts Holdings in Aspen Aerogels, Inc. $ASPN
AWM Investment Company Inc. lowered its position in Aspen Aerogels, Inc. (NYSE: ASPN) by 41.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,435,477 shares of the construction company's stock after selling 1,013,744 shares during the quarter. AWM Investment Company Inc. owned
Aspen Aerogels, Inc. (NYSE:ASPN) Given Consensus Recommendation of “Hold” by Analysts
Shares of Aspen Aerogels, Inc. (NYSE: ASPN - Get Free Report) have been assigned a consensus rating of "Hold" from the ten analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, four have given a buy recommendation and
Here's What Key Metrics Tell Us About Aspen Aerogels (ASPN) Q3 Earnings
Although the revenue and EPS for Aspen Aerogels (ASPN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aspen Aerogels, Inc. (ASPN) Q3 2025 Earnings Call Transcript
Aspen Aerogels, Inc. ( ASPN ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Neal Baranosky - Senior Director of Corporate of Strategy & Finance Donald Young - President, CEO & Director Grant Thoele - Treasurer & CFO Conference Call Participants Eric Stine - Craig-Hallum Capital Group LLC, Research Division Colin Rusch - Oppenheimer & Co. Inc., Research Division Ryan Pfingst - B. Riley Securities, Inc., Research Division John Anderson - Barclays Bank PLC, Research Division Leanne Hayden - Canaccord Genuity Corp., Research Division Presentation Operator Good morning.
Aspen Aerogels, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call
NORTHBOROUGH, Mass. , Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company") today announced that Don Young, President and Chief Executive Officer, and Grant Thoele, Chief Financial Officer and Treasurer, expect to discuss the Company's financial results for the third quarter ended September 30, 2025, during a conference call scheduled for Thursday, November 6, 2025, at 8:30 a.
Aspen Aerogels, Inc. (ASPN) Presents At Barclays 39th Annual CEO Energy-Power Conference 2025 Transcript
Aspen Aerogels, Inc. (NYSE:ASPN ) Barclays 39th Annual CEO Energy-Power Conference 2025 September 3, 2025 9:45 AM EDT Company Participants Ricardo Rodriguez - CFO & Treasurer Conference Call Participants John Anderson - Barclays Bank PLC, Research Division Presentation John Anderson Director and Senior North America Oilfield Services & Equipment Analyst So we don't know of too many companies quite like Aspen Aerogels. We often talk about transferable skill sets in energy services, products and services in traditional energy.
Aspen Aerogels (ASPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Aspen Aerogels (ASPN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Aspen Aerogels, Inc. (ASPN) Q2 2025 Earnings Call Transcript
Aspen Aerogels, Inc. (NYSE:ASPN ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Donald R. Young - President, CEO & Director Neal Baranosky - Senior Director of Corporate of Strategy & Finance Ricardo C.
Aspen Aerogels (ASPN) Reports Q2 Loss, Tops Revenue Estimates
Aspen Aerogels (ASPN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.21 per share a year ago.
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Patient insights informed the development of pilavapadin, Lexicon's investigational, novel, non-opioid treatment for people suffering from DPNP Patient insights informed the development of pilavapadin, Lexicon's investigational, novel, non-opioid treatment for people suffering from DPNP
Aspen Aerogels (ASPN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Aspen Aerogels (ASPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Aspen Aerogels, Inc. (ASPN) Q1 2025 Earnings Call Transcript
Aspen Aerogels, Inc. (NYSE:ASPN ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Neal Baranosky - Senior Director of Corporate of Strategy & Finance Don Young - President and CEO Ricardo Rodriguez - CFO and Treasurer Conference Call Participants Colin Rusch - Oppenheimer David Anderson - Barclays Eric Stine - Craig-Hallum Leanne Hayden - Canaccord Operator Good morning. Thank you for attending the Aspen Aerogels First Quarter 2025 Financial Results Call.